BridgeMD
New treatment option for Ischemic Stroke
Official title Acetyl-leucine in Post-stroke Ataxia
ClinicalTrials.gov ID: NCT07275749
What this study is testing
What is Acetyl-Leucine?
Acetyl-Leucine is an investigational medicine, given as an once-daily, being studied as a potential treatment for ischemic stroke.
Also referred to as group A.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Along with the current clinical trial, the efficacy and safety of 4 gram of acetyl-leucine daily for three months in patients with post-stroke ataxia following posterior-circulation ischaemic stroke assessed through BBS, SARA, and mRS, and possible adverse effects.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- the investigators included both males and females, aged between 18 and 80 years, who experienced their first-ever posterior-circulation ischaemic...
- All of our patients underwent randomisation during the first 24 hours of the symptoms' onset, and within the first 24 hours from the time at which...
You likely can't join if
- the investigators excluded patients with modified Rankin Scale (mRS) score of 5 or more, physical or mental conditions that would not allow safe...
- the investigators ruled out participants who suffered from neurological diseases associated with recurrent neurological deficits, such as (epilepsy...
- the investigators excluded participants who underwent intravenous thrombolysis, carotid, cerebrovascular, or coronary revascularization during the...
- the investigators excluded patients who experienced recurrent ischemic stroke detected from their clinical data and/or magnetic resonance imaging...
- the investigators excluded participants who experienced organ failure such as renal failure and liver cell failure, active malignancies, and patients...
The study team makes the final eligibility decision.
Where it's taking place
- Kafr ash Shaykh, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Kafr ash Shaykh, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.